MedPath

Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT

Phase 2
Completed
Conditions
Genital Lichen Planus
Interventions
Registration Number
NCT01282515
Lead Sponsor
Oslo University Hospital
Brief Summary

To compare the effect and side effects of photodynamic treatment and traditional topical steroid treatment in female genital erosive lichen planus

Detailed Description

To assess the feasibility, efficacy and safety of hexyl 5-aminolevulinate-hydrocloride (HAL)-PDT in GELP in women.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria

Women with symptomatically genital ELP, clinically verified by at least one doctor attended to the Vulva clinic.

Untreated for ELP for at least 4 weeks. Written Informed Consent signed Age 18 or above

Exclusion Criteria

Current pelvic inflammatory disease, genital malignancy, or gynecological infection.

Known or suspected porphyria

Known allergy to hexaminolevulinate or similar compounds (e.g. hexaminolevulinate or aminolevulinic acid) Pregnancy and lactation Participation in other clinical study either concurrently or within the last 30 days

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ELP activehexaminolevulinateone PDT treatment with 2 ml hexaminolevulinate 6 mg/ml gel
topical steroidsclobetasol propionate 0,05% ointmenttreatment with clobetasol propionate 0.05% ointment used daily for 6 weeks
Primary Outcome Measures
NameTimeMethod
Percentage change of GELP score and/or VAS score 6 weeks after start of treatment.6 weeks
Secondary Outcome Measures
NameTimeMethod
Percentage change of GELP score and/or VAS score 6 months after start of treatment.6 months

Trial Locations

Locations (1)

Rikshospitalet, OsloUniversity hospital

🇳🇴

Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath